Johnson & Johnson News

Johnson & Johnson is a large and diverse company, so staying up-to-date with developments, company performance, and their plans for the future is not easy. That's why Wiser created the Johnson & Johnson news digest. It is delivered once a day and contains the key articles from around the web in order to keep you informed. Johnson & Johnson is primarily involved in the health sector. Its interests are spread across 275 different companies in 60 countries. It was founded in 1886 and its headquarters is in New Jersey. Worldwide it employs about 128,000 people and its main consumer brands include Band-Aid, Johnson's baby products and Neutrogena. It also has a medical devices and diagnostics sector, and a pharmaceuticals sector. Challenges exist in the later, particularly regarding the competition from generic versions of some of its drugs. Its research and development pipeline is also watched with interest, as is its movements in terms of expansion - further acquisitions, particularly in the medical devices field, are expected. Make sure you do not miss any Johnson & Johnson news, analysis or information by registering for the free Wiser daily email.

Recent Johnson & Johnson News Coverage
 
Your Weekly Recommendations Monday, May 29, 2017
 
Recommended for you
Week In Review: China Life Science Venture Tie-Up: WuXi And Frontline Merge
Seeking Alpha • Chinabio Today
Johnson & Johnson To Pay $33M In Investigation Over Manufacturing Practices
Kaiser Health News
Johnson & Johnson (JNJ) Investor Presentation (Pharmaceutical Business Review Day) - Slideshow
Seeking Alpha
Johnson & Johnson settles drug manufacturing probe by US states for $33 million
The Economic Times of India
DePuy Synthes, XpandOrtho, Zimmer Biomet & more: 13 device company key notes
Becker's Spine Review • Anuja Vaidya
Johnson & Johnson Lays Out Its Battle Plan
Seeking Alpha • E.P. Vantage
Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy
Reuters
Johnson & Johnson: The Right Way To Play This Dividend Champion
Seeking Alpha • Justin Pope
Johnson & Johnson Unveils Ambitious Multi-Billion Dollar Plan
Fortune Magazine • Sy Mukherjee
Johnson & Johnson plans to file for approval 10 potential blockbusters in next 4 years
MarketWatch • Gertrude Guth
 
Recommended for You
Cancer, Google Inc
Week In Review: China Life Science Venture Tie-Up: WuXi And Frontline Merge
Seeking AlphaChinabio Today
Deals and Financings Two prominent China-US healthcare investment firms plan to join forces. WuXi Healthcare Ventures and Frontline BioVentures will merge to form 6 Dimensions Capital. Together, the two firms have almost $800 million under management. 6 Dimensions plans to continue growing...
Share
Health Reform, Johnson & Johnson
Johnson & Johnson To Pay $33M In Investigation Over Manufacturing Practices
Kaiser Health News
“Johnson & Johnson’s disregard for proper manufacturing practices of children’s medications was unacceptable,” says Illinois Attorney General Lisa Madigan in a statement.
Share
Health Finance, Johnson & Johnson
Johnson & Johnson (JNJ) Investor Presentation (Pharmaceutical Business Review Day) - Slideshow
Seeking Alpha
The following slide deck was published by Johnson & Johnson in conjunction with this event.
Share
Johnson & Johnson, Pfizer, Inc.
Johnson & Johnson settles drug manufacturing probe by US states for $33 million
The Economic Times of India
Johnson & Johnson has agreed to pay $33 million to resolve charges by most US states that it misrepresented the manufacturing practices behind Tylenol, Motrin, Benadryl and other over-the-counter drugs that were eventually recalled. The settlement, announced by attorneys general for 42...
Share
Economic Policy, Health Care Industry
DePuy Synthes, XpandOrtho, Zimmer Biomet & more: 13 device company key notes
Becker's Spine ReviewAnuja Vaidya
Here are 13 key notes on orthopedic and spine device companies from the past week. DePuy Synthes, a Johnson & Johnson company, received a national contract from the U.S. Department of Defense for its orthopedic products. Orthofix reported a net sales increase...
Share
Actelion Pharmaceuticals, Cancer
Johnson & Johnson Lays Out Its Battle Plan
Seeking AlphaE.P. Vantage
Johnson & Johnson's (NYSE:JNJ) pharma engine is faltering, and it needs more fuel. But it is unclear whether its list of potential new blockbusters will give it the boost it needs. Among the 11 projects highlighted - plus ponesimod, which it will...
Share
Biotechnology, Health Care Industry
Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy
Reuters
SEOUL (Reuters) - A unit of healthcare conglomerate Johnson & Johnson filed a lawsuit to block a copy of its rheumatoid arthritis drug Remicade made by South Korea's Samsung Bioepis Co Ltd from being sold in the United States.
Share
Abbott Laboratories, Economic Policy
Johnson & Johnson: The Right Way To Play This Dividend Champion
Seeking AlphaJustin Pope
Summary Shares of the healthcare conglomerate are cruising along near 52 week highs. Yet when you look closer, the valuation isn't as absurd as one might expect in an overheated market. However a wise investor NEVER trades in and out of Johnson...
Share
Biotechnology, Cancer
Johnson & Johnson Unveils Ambitious Multi-Billion Dollar Plan
Fortune MagazineSy Mukherjee
Johnson & Johnson isn't resting on its laurels. The drug giant said on Wednesday that it wants to get more than ten of it experimental "blockbuster" drugs—i.e., those that could rake in at least $1 billion in sales every year—either on the...
Share
Finance, Johnson & Johnson
Johnson & Johnson plans to file for approval 10 potential blockbusters in next 4 years
MarketWatchGertrude Guth
Johnson & Johnson said Wednesday that it, along with its Janssen Pharmaceutical Companies, plans to file for regulatory approval 10 new potential blockbuster drugs between this year and 2021. The company said it also plans more than 50 line extensions of existing...
Share